{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwP3awbAJDA","lastupdate":"2024-05-08T00:00:00.000Z","update_date":"2024-05-08T00:00:00.000Z","lastModified":"Mar 16, 2025","active":1,"confidence_score":98,"confidence_score_reason":"video or image, markets","urlname":"tarsius-pharma","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$pZ7lCvYpBRlIIhk028HlwYH78CACNKCTpePsoWzDqO4QSQrgaWQniB","name":"Tarsier Pharma","oneliner":"Novel Treatments for Autoimmune Inflammatory Ocular Diseases ","registrar":"515398642","website":"https://tarsierpharma.com","careerspage":"","founded_month":1,"founded_year":2016,"formernames":["Tarsius Pharma"],"sociallinks":{"twitter":"https://twitter.com/TarsierPharma","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/34220421","instagram":""},"social":["https://www.linkedin.com/company/34220421","https://twitter.com/TarsierPharma"],"flattenedsociallinks":"https://www.linkedin.com/company/34220421|https://twitter.com/TarsierPharma","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":12,"patent":1,"raised":5650000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"Tarsier Pharma is a late-clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune inflammatory ocular diseases. \r\n\r\nThe TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases. It is currently being developed as both eye drops and intravitreal injections. TRS has the potential to effectively control a range of autoimmune and inflammatory ocular diseases as potently as steroids but without the negative side effects.\r\n\r\nThe company's investors include a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd, as well as private investors and family offices. \r\n\r\nThe company has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 879598.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"87fcfd8c-aaf8-4637-8865-ccc410aaa2b9","city":"Zikhron Ya'akov","type":null,"address":"Yahalom 19, Zikhron Ya'akov, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"2Say2HUnJqWuQK1WleBz8rNvb4TzUcofGRPAylvwnnZIPEGYbphFyG","date":"Jan 7, 2025","link":"https://www.prnewswire.com/il/news-releases/tarsier-pharma-appoints-ashley-kline-as-chief-commercial-officer-expanding-its-us-presence-302344307.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes","round":null,"company":"Tarsier Pharma Ltd","layoffs":null,"summary":"Tarsier Pharma Ltd, a late-clinical stage ophthalmic biopharmaceutical company, has appointed Ms. Ashley Kline as Chief Commercial Officer. With over 15 years of experience in biopharmaceuticals, particularly in ophthalmology, Kline will lead the commercial planning for Tarsiers pipeline, including its lead asset, TRS01. Her previous roles at Dompé Farmaceutici and other companies have equipped her with the expertise to bring novel therapies to market. Tarsier is focused on developing treatments for blinding ocular diseases, with TRS01 entering its second phase 3 trial. This appointment is seen as a pivotal step in Tarsiers growth, aiming to build commercial franchises in uveitis and other blinding conditions.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["ophthalmology","uveitis","leadership","clinical trials","commercialization"],"date_of_event":null,"product_stage":"late-clinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0LxfJjFmUqbbpEeAJ9PtKNc5kM6IREAr6EO6E5jng6XZ2vXMRhwkVH","news_summary":"/PRNewswire/ -- Tarsier Pharma®, Ltd, a late-clinical stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"E8ZP94vWNee6DLC5uSFa5AVcXvx8ng3BhQwE5rrYY1xXVssW5IIiw8","date":"Aug 15, 2022","link":"https://www.prnewswire.com/news-releases/tarsier-pharma-announces-development-of-trs02-a-potential-immunomodulator-for-the-treatment-of-retinal-diseases-with-sustained-release-intravitreal-formulation-301605537.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"pharmaceutical, therapeutics","company":"Tarsier Pharma","layoffs":null,"summary":"Tarsier Pharma has announced the development of TRS02, a slow-release formulation of TRS for intravitreal injection, to treat retinal diseases. TRS is a breakthrough proprietary technology platform with an anti-inflammatory Mechanism-of-Action. TRS02 is intended to be injected into the back of the eye for the treatment of back-of-the-eye indications with underlying inflammatory pathology. The company has achieved significant pre-clinical milestones in TRS02 development, bringing it closer to IND submission. Tarsier Pharma is focused on developing technologies to treat ocular back and front of the eye blinding diseases.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["TRS02","retinal diseases","inflammatory pathology","slow-release formulation","clinical trial"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iHpuXkFRLg32UKlx818byHcuPXwilDaHvVJyYXcF2oPJSNt6lfcNlR","news_summary":"Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"EGkilZrO6XlwkXqqeB80klSC0LKapoBMWQEDDiE52mzlI3SNlkM2vQ","date":"Feb 4, 2022","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3928585,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Biotech, Uveitis Treatment","company":"Tarsier Pharma","layoffs":"Not mentioned","summary":"Tarsier Pharma, a biotech company founded by Dr. Daphne Haim-Langford, is developing medical solutions for autoimmune and inflammatory eye diseases. The companys flagship product combats Uveitic glaucoma, a condition that can cause blindness and is currently in stage three of its clinical trials. Since its founding, Tarsier Pharma has raised $20 million from investors including Indian biopharmaceutical giants Sun Pharmaceutical Industries Ltd. and BioLite Life Sciences. The company plans to file its trial results to the FDA by 2023.","partners":"Not mentioned","customers":"Not mentioned","investors":["Sun Pharmaceutical Industries Ltd.","BioLite Life Sciences"],"confidence":9,"key_topics":["Uveitis Treatment","Clinical Trials","Investment","Company Growth","Personal Journey"],"date_of_event":"04.02.22","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tuIJDEVrolsNCEx4hLlS38R9718WEhQgUp0M1nc4DMGxg0YOHhDd2v","news_summary":"How one female CEO overcame adversity to find a cure for Uveitis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"M55AZCcU9TCG6n9P5aQmVABk6D1GtbzQas9WV0yeeR31ojchAA4Ghc","date":"Jan 5, 2022","link":"https://www.prnewswire.com/news-releases/tarsier-pharma-is-launching-a-dedicated-website-about-uveitic-glaucoma-301454470.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"pharmaceutical, ocular diseases","company":"Tarsier Pharma","layoffs":null,"summary":"Tarsier Pharma has launched an education website about the disease uveitic glaucoma to increase awareness among the general public. Uveitic glaucoma is a severe and blinding disease that consists of non-infectious uveitis and glaucoma. The companys lead product candidate, TRS01, is a fast-acting immunomodulator for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma. Tarsier Pharma aims to develop optimal therapies for this patient population.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["uveitic glaucoma","disease awareness","clinical trial","ocular diseases","treatment development"],"date_of_event":"January 5, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Yfo9wJuqu3wU9pJmaOxsgSiDWBGjxZonQfv7TzXnwtcvu5epqDjGC5","news_summary":"Tarsier™ Pharma is launching a dedicated website about uveitic glaucoma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6e463097-c747-4809-b08d-164af5d718f8","date":"Dec 1, 2021","link":"https://www.timesofisrael.com/israeli-pharmaceutical-executive-wins-2021-eu-prize-for-women-innovators/","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":["prize","women innovators","pharmaceutical","awards"],"company":"Tarsier Pharma","layoffs":null,"summary":"Dr. Daphne Haim-Langford, founder and CEO of Tarsier Pharma, won the 2021 EU Prize for Women Innovators. Tarsier Pharma, founded in 2016, develops treatments for autoimmune inflammatory ocular diseases. The prize comes with a €100,000 cash prize. Tarsier Pharma has received funding from the EUs Horizon Europe program. Earlier this year, Tarsier Pharma raised capital to perform a phase III clinical trial of one of its solutions, TRS, in the US and Europe.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["EU Prize for Women Innovators","Tarsier Pharma","pharmaceutical company","autoimmune inflammatory ocular diseases","funding program"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZFuuzvCRDoqSQ4tE9aFxgfwgrN38BSBE4KseiFmAOXgnHLWCAWJqcs","news_summary":"Israeli pharmaceutical executive wins 2021 EU Prize for Women Innovators","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0a9a0e1f-0b56-4b39-a3a0-c959cb849890","date":"Aug 24, 2021","link":"https://www.prnewswire.com/news-releases/tarsier-pharma-raises-capital-to-execute-phase-3-clinical-trial-301361616.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"pharmaceutical, clinical trial","company":"Tarsier Pharma","layoffs":null,"summary":"Tarsier Pharma has raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. The company obtained all necessary regulatory approvals and plans to enroll the first patient in Q4 of 2021. Tarsiers TRS technology is a novel immunomodulator molecule that has shown significant improvement in signs and symptoms of uveitis. The CEO of Tarsier Pharma expressed excitement about bringing their lead product to market and progressing the development of pipeline projects for other blinding diseases.","partners":null,"customers":null,"investors":"strategic and new investors alongside existing investors","confidence":9,"key_topics":["clinical trial","immunomodulator molecule","uveitis","ocular diseases","capital raise"],"date_of_event":"August 24, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5NCJYmWtPKDsyumqmtnTPZrNplM8VQmru4yFPYx38ZLIuNLkVNPJRy","news_summary":"Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d30055ea-d62a-4428-8438-5e4f9792ea20","date":"Dec 17, 2020","link":"https://www.biospace.com/article/releases/tarsier-pharma-s-positive-end-of-phase-2-meeting-with-the-u-s-fda-sets-stage-for-trs01-phase-iii-program-in-uveitis/?s=68","source":"www.biospace.com","visible":1,"analysis":{"tags":"pharmaceutical, clinical stage, therapeutics, FDA, trial design, program, immunomodulator drug, uveitis, NDA, inflammation, glaucoma","company":"Tarsier Pharma","layoffs":null,"summary":"Tarsier Pharma has successfully completed an End-of-Phase 2 meeting with the FDA for its TRS01 Phase 3 program in uveitis. The company received important feedback on its trial design and program, paving the way for a future NDA submission. TRS01 is a novel immunomodulator drug for treating Active Anterior Non-Infectious Uveitis. Tarsier Pharma plans to initiate the pivotal Phase 3 study in 2021. Positive results from the Phase 1/2 clinical trial of TRS01 showed significant improvement in signs and symptoms of Uveitis. Tarsier Pharma is focused on developing TRS, a breakthrough platform technology for the treatment of ocular diseases.","partners":["Sun Pharmaceutical Industries Limited","BioLight Life Sciences Ltd"],"customers":null,"investors":["Sun Pharmaceutical Industries Limited","BioLight Life Sciences Ltd"],"confidence":9,"key_topics":["Tarsier Pharma","TRS01 Phase 3 program","clinical trial","uveitis","glaucoma"],"date_of_event":"2020-12-17","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"weze3gZx1cOFHxRFqZsHhR6mn4X2Z7j7v425aESjAPH000uMqFSHAU","news_summary":"Tarsier Pharma's Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in Uveitis BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"decf99f0-0574-4894-abb0-5e1cf82b0499","date":"Oct 5, 2020","link":"https://www.prnewswire.com/news-releases/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis-301145540.html#:~:text=5%2C%202020%20%2FPRNewswire%2F%20%2D%2D,Anterior%20Non%2DInfectious%20Uveitis%2C%20demonstrated","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"biopharmaceutical, ocular diseases","company":"Tarsius Pharma","layoffs":null,"summary":"Tarsius Pharma announced positive results from the GADOT 20/20 trial of its TRS01 drug for treating Active Anterior Non-Infectious Uveitis. The trial demonstrated significant improvement in critical measures such as ACC, pain reduction, and increased visual acuity. The high-dose usage of TRS01 was found to be superior to the low-dose in various measures. The results suggest progress towards the development of a novel class of ocular therapeutics. Tarsius Pharma is focused on developing TRS, a breakthrough platform technology for the treatment of blinding ocular diseases.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["GADOT 20/20 trial","TRS01 drug","ocular diseases","uveitis","clinical trial"],"date_of_event":"October 5, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4ryxItKbUJwx3aorwNBRYqslEMYBUD55iKhPsCQKspaogg4vMVtswB","news_summary":"Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"605a6774-41aa-412c-b155-d8794253607f","date":"Jun 22, 2020","link":"https://www.prnewswire.com/news-releases/tarsius-pharma-completes-patient-enrollment-in-clinical-trial-of-trs01-in-patients-with-non-infectious-uveitis-301080960.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical-stage biopharmaceutical","company":"Tarsius Pharma","layoffs":null,"summary":"Tarsius Pharma has announced the completion of patient enrollment in its Phase I/II trial of TRS01 for the treatment of ocular inflammation. The trial, called GADOT 20/20, aims to evaluate the safety and efficacy of TRS01 in patients with active anterior non-infectious uveitis. Despite the challenges posed by the COVID-19 pandemic, the company exceeded its enrollment target and enrolled 16 patients. Tarsius Pharma expects to announce topline results from the trial in the second half of 2020. The completion of enrollment marks an important milestone for the company and highlights the urgent need for better treatment options for patients with uveitis. Tarsius Pharma plans to commence the Phase III trial in early 2021. The companys investors include Sun Pharmaceuticals and BioLight Life Sciences Ltd.","partners":null,"customers":null,"investors":["Sun Pharmaceuticals","BioLight Life Sciences Ltd"],"confidence":9,"key_topics":["ocular inflammation","Phase I/II trial","TRS01","uveitis","enrollment"],"date_of_event":"June 22, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"istkrUOJoEC17XCvk8emnfUDb4n71RcXIS1BkmDumtQlGzG7PqdVSW","news_summary":"Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e9d0e9d1-257e-404e-91c5-3dfd499c61c9","date":"Nov 19, 2019","link":"https://www.prnewswire.com/il/news-releases/tarsius-pharma-announces-granting-of-orphan-drug-designation-for-trs-by-the-european-medicines-agency-300960991.html#:~:text=19%2C%202019%20%2FPRNewswire%2F%20%2D%2D,TRS%20in%20non%2Dinfectious%20uveitis","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Orphan drug designation","company":"Tarsius Pharma","layoffs":null,"summary":"Tarsius Pharma has received orphan drug designation from the European Medicines Agency (EMA) for its TRS for the treatment of non-infectious uveitis. The EMA acknowledged the significant benefit of TRS for uveitis patients with glaucoma who are not eligible for corticosteroid treatment. This designation allows Tarsius Pharma to proceed to Phase I/II clinical trials. Ocular inflammatory diseases, including uveitis, impose a significant burden on society and can lead to vision loss and blindness. Tarsius Pharmas TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases. Tarsius Pharma was established in 2016 and has received funding from the European Unions Horizon 2020 program. The companys investors include Sun Pharmaceuticals, BioLight Life Sciences Ltd, private investors, and family offices.","partners":null,"customers":null,"investors":["Sun Pharmaceuticals","BioLight Life Sciences Ltd","private investors","family offices"],"confidence":9,"key_topics":["Orphan drug designation","Treatment for non-infectious uveitis","Glaucoma","Clinical trials","Ocular inflammatory diseases"],"date_of_event":"November 19, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NDXB0yaUiLNcZ3BBloBDrc3gOLXif5YsnYACeZCACgC35kjTsk1czu","news_summary":"Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agency","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6058143e-b08b-4eed-9ed9-dc82260b9584","date":"Sep 24, 2019","link":"https://www.prnewswire.com/news-releases/tarsius-pharma-announces-fda-acceptance-of-ind-application-for-trs01-300924118.html#:~:text=24%2C%202019%20%2FPRNewswire%2F%20%2D%2D,treatment%20of%20blinding%20ocular%20diseases.","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"bio-inspired platform technology","company":"Tarsius Pharma","layoffs":null,"summary":"Tarsius Pharmas Investigational New Drug (IND) application for TRS01 has been accepted by the FDA. TRS01 is a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases. The acceptance of the IND will allow Tarsius to initiate enrollment in its planned Phase I/II clinical trial of TRS01. The study aims to determine the safety profile, recommended dose, and potential effect of TRS01 in ocular inflammation. Tarsius Pharma is focused on developing innovative therapeutic solutions to prevent blindness and is backed by Sun Pharmaceuticals and other private investors. Ocular inflammatory diseases impose a significant burden on society, and the TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases.","partners":null,"customers":null,"investors":"Sun Pharmaceuticals","confidence":9,"key_topics":["Investigational New Drug","TRS01","ocular diseases","clinical trial","FDA acceptance"],"date_of_event":"September 24, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jzotT1cJRCRMGwq2gsuPseg2zf8cNoquMsauKNLxSflRLLLbDA1k7E","news_summary":"Tarsius Pharma Announces FDA Acceptance of IND Application for TRS01","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"10bc007a-2ddb-482f-8032-c9682c4694ce","date":"Sep 18, 2019","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3770582,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"funding, clinical development","company":"Tarsius Pharma Ltd.","layoffs":null,"summary":"Israel-based Tarsius Pharma Ltd. has been awarded a 2.4 million euros grant from Horizon 2020, the European Union’s research and innovation program. The funding will be used to start clinical development for Tarsius technology in the treatment of blindness-causing ocular diseases. Tarsius Pharma Ltd. develops treatments for autoimmune and inflammatory diseases that damage the eye. The company is based in Zikhron Yaakov, Israel. Horizon 2020 is carried out in Israel by the Israel Innovation Authority through the Israel-Europe Research and Development Directorate.","partners":["Horizon 2020","Israel Innovation Authority","Israel-Europe Research and Development Directorate"],"customers":null,"investors":null,"confidence":8,"key_topics":["funding","clinical development","Horizon 2020","ocular diseases","Israel"],"date_of_event":"2019-09-18","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"2.4 million euros","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cmUBB5q7XpNYeDhaHjj3cHvAVWsOs2dIGKmEbldU5JCZyDJUeln5zD","news_summary":"Tarsius Pharma Receives 2.4 Million Euros EU Grant to Combat Blinding Diseases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"472c3b0d-202b-444e-9af6-faaa4fc04352","date":"Sep 11, 2018","link":"https://www.dealstreetasia.com/stories/sun-pharma-tarsius-106457/","source":"www.dealstreetasia.com","visible":1,"analysis":{"tags":"acquisition","company":"Sun Pharmaceutical Industries","layoffs":null,"summary":"Sun Pharmaceutical Industries is acquiring an 18.75% stake in Tarsius Pharma for a cash consideration of $3 million.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Sun Pharmaceutical Industries","Tarsius Pharma","acquisition","stake","cash consideration"],"date_of_event":"11 September, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":"$3 million","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GVZ9YTByly7JaxOKfIk9Tnz9ZY1LpNhG9FRW6JnWjid6tfrt3aYWfS","news_summary":"Sun Pharma to acquire 18.75% stake in Israel's Tarsius for $3m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":13,"techcommunityinvolvement":null,"mediagallery":[],"tags":["pharmaceuticals","eye-diseases","drug-discovery","anti-inflammatory","orphan-drug","autoimmune-diseases","inflammatory-diseases"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["TRS01","TRS02"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":3,"lastfunding":"Undisclosed","totalrounds":3,"fundingstage":"Seed","totalfunding":"$5.65M","publicinvestors":1,"lastpublicfunding":0,"totalpublicrounds":1,"totalpublicfunding":0},"team":[{"name":"Susan Benton","email":"skbenton@icloud.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NOhtP8LDA","bounced":false,"claimed":0,"founder":0,"urlname":"susan-benton","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg47LwswoM","position":"Board Member","last_name":"Benton","claimtoken":"84b5a596b307f009eac62990c2db7b0734533020c9d5941b33c317e5a519111e","first_name":"Susan","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/susanbenton2020/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-12-15 20:34:57.000000","initials":"SB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Daphne Haim-Langford, Ph.D.","email":"daphne@tarsiuspharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwL2Nn4MIDA","bounced":false,"claimed":0,"founder":1,"urlname":"daphne-haim-langford-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAvbmDpAsM","position":"Co-Founder & CEO","last_name":"Haim-Langford, Ph.D.","claimtoken":"rIasbZBXUJs00gstdIjG61wVWg0GfRgswZVf2VAkgFWDE8LouUW8YO","first_name":"Daphne","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/daphnehaimlangford/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-08-29 12:18:30.000000","initials":"DH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ron Neumann","email":"ron@tarsiuspharma.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4PKfq5QKDA","bounced":true,"claimed":0,"founder":0,"urlname":"ron-neumann-3","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgssupwQgM","position":"CMO","last_name":"Neumann","claimtoken":"VpKcHF27YaUToflA2L6XWYOUoH87scB7DBhOYcMzTKKKrfRlMqTg2X","first_name":"Ron","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/roneumann/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-08-29 12:18:41.000000","initials":"RN","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Zohar Milman","email":"zohar@tarsiuspharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4PKwnb8LDA","bounced":false,"claimed":0,"founder":0,"urlname":"zohar-milman","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgkrjEuwgM","position":"COO","last_name":"Milman","claimtoken":"hUCr6ozkFHVTUNw2ArKM1MXMKfvOuwaHgpgg5pVrNelWev2LpUaVIr","first_name":"Zohar","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/zohar-milman-0b092540/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-08-29 12:18:36.000000","initials":"ZM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ruth Friedel","email":"ruti@tarsiuspharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4KPgsd8KDA","bounced":true,"claimed":1,"founder":0,"urlname":"ruth-friedel-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg08LhwgkM","position":"Business Development Manager","last_name":"Friedel","claimtoken":"ff37768fc2b4dc827856d7f8b3f38b4e9859753cfb3f76427d5a487cfbb7e3cf","first_name":"Ruth ","picturekey":null,"claimeddate":"2020-12-15","linkedinurl":"https://www.linkedin.com/in/ruth-friedel-b110175b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-12-15 17:01:57.000000","initials":"RF","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2019-09-19T00:00:00.000Z","crunchbaseid":"tarsius-pharma-ltd","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Natalia Golczar","creator_email":"ngolczar@gmail.com","createdate":"2017-03-02T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCQgvODCgw","date":"Aug 2021","amount":"Undisclosed","source":"https://maya.tase.co.il/reports/details/1396562/2/0","eventtype":"FundingRoundEvent","investment":[{"name":"BIOLIGHT Life Sciences","type":"Investor","amount":250000,"hidden":false,"country":"Israel","fullurl":"/investor_page/biolight-life-sciences","logokey":"$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","tagline":null,"urlname":"/investor_page/biolight-life-sciences","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OeL444IDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6d488cc1-886a-431d-8876-7d2c5a6a9b78","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCS_4vFCww","date":"Sep 2019","amount":"$2.65M","source":"Added by Ruth Friedel","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"EU Horizon 2020","type":"Other","amount":0,"hidden":false,"country":"Belgium","fullurl":"/company_page/eu-horizon-2020","logokey":"$Y11JsXnB1FT2S0h1lyXUQMAhH6bM0g2tSIdWQAjTFxivAoweBwRj4g","tagline":"","urlname":"/company_page/eu-horizon-2020","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE7vSzCgw","fundingtype":"Other","leadpartner":null,"investmentid":"f798780e-8753-4cfc-9398-0156d8ed8e66","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y11JsXnB1FT2S0h1lyXUQMAhH6bM0g2tSIdWQAjTFxivAoweBwRj4g","leadcaption":"","followupcaption":""}],"eventvisibility":"Private","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='\n\n
\n \n \n Private\n
'","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2650000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2q_0CQw","date":"Sep 2018","amount":"$3M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Sun Pharmaceutical Industries (India)","type":"Company","amount":0,"hidden":true,"country":"India","fullurl":"/company_page/sun-pharmaceutical-industries-india","logokey":"$XCWKlrYAgZfyYZ33Q09lo0JHyhNrrSWbqZUPXoiHBf5QjbfvjpHc28","tagline":"","urlname":"/company_page/sun-pharmaceutical-industries-india","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEvIzHCww","fundingtype":"Company","leadpartner":null,"investmentid":"vyJsvMwJVledLjt2cSFaUclqilmuVTtfWZauOgFgZc9LEGNXo3AarL","fundingsubtype":"","investorislead":0,"amountvisibility":"Private","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XCWKlrYAgZfyYZ33Q09lo0JHyhNrrSWbqZUPXoiHBf5QjbfvjpHc28","leadcaption":"","followupcaption":""},{"name":"Xenia Venture Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/xenia-venture-capital","logokey":"$MfqF5WmAKFiams13nTMLjr0ZOy38PqXIOUgyA5BitfcqqGAkeKEBmb","tagline":null,"urlname":"/investor_page/xenia-venture-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNGDmIcKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"w71TaMG2kEMUBsFNPwRHmEpOjKt5i2ZPCHqN60YpKeQ9fZJ7DA1G6s","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$MfqF5WmAKFiams13nTMLjr0ZOy38PqXIOUgyA5BitfcqqGAkeKEBmb","leadcaption":"","followupcaption":""}],"eventvisibility":"Private","amountvisibility":"Private","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='\n\n
\n \n \n Private\n
'","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2016","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Tarsier Pharma","logourl":"https://storage.googleapis.com/clean-finder-353810/$pZ7lCvYpBRlIIhk028HlwYH78CACNKCTpePsoWzDqO4QSQrgaWQniB","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$pZ7lCvYpBRlIIhk028HlwYH78CACNKCTpePsoWzDqO4QSQrgaWQniB","seoabout":"Tarsier Pharma is a late-clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and sa...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Biotechnology","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"},{"title":"Pharmaceuticals","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Biotechnology","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCQgvODCgw","date":"Aug 2021","amount":"Undisclosed","source":"https://maya.tase.co.il/reports/details/1396562/2/0","eventtype":"FundingRoundEvent","investment":[{"name":"BIOLIGHT Life Sciences","type":"Investor","amount":250000,"hidden":false,"country":"Israel","fullurl":"/investor_page/biolight-life-sciences","logokey":"$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","tagline":null,"urlname":"/investor_page/biolight-life-sciences","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OeL444IDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6d488cc1-886a-431d-8876-7d2c5a6a9b78","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$o8uyrhM0wkd8QeEmyBfNubbEEho5Lj78MYmFcMCSp47nIciiCCyo5h","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2q_0CQw","date":"Sep 2018","amount":"$3M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Sun Pharmaceutical Industries (India)","type":"Company","amount":0,"hidden":true,"country":"India","fullurl":"/company_page/sun-pharmaceutical-industries-india","logokey":"$XCWKlrYAgZfyYZ33Q09lo0JHyhNrrSWbqZUPXoiHBf5QjbfvjpHc28","tagline":"","urlname":"/company_page/sun-pharmaceutical-industries-india","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEvIzHCww","fundingtype":"Company","leadpartner":null,"investmentid":"vyJsvMwJVledLjt2cSFaUclqilmuVTtfWZauOgFgZc9LEGNXo3AarL","fundingsubtype":"","investorislead":0,"amountvisibility":"Private","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XCWKlrYAgZfyYZ33Q09lo0JHyhNrrSWbqZUPXoiHBf5QjbfvjpHc28","leadcaption":"","followupcaption":""},{"name":"Xenia Venture Capital","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/xenia-venture-capital","logokey":"$MfqF5WmAKFiams13nTMLjr0ZOy38PqXIOUgyA5BitfcqqGAkeKEBmb","tagline":null,"urlname":"/investor_page/xenia-venture-capital","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNGDmIcKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"w71TaMG2kEMUBsFNPwRHmEpOjKt5i2ZPCHqN60YpKeQ9fZJ7DA1G6s","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$MfqF5WmAKFiams13nTMLjr0ZOy38PqXIOUgyA5BitfcqqGAkeKEBmb","leadcaption":"","followupcaption":""}],"eventvisibility":"Private","amountvisibility":"Private","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='\n\n
\n \n \n Private\n
'","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCS_4vFCww","date":"Sep 2019","amount":"$2.65M","source":"Added by Ruth Friedel","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"EU Horizon 2020","type":"Other","amount":0,"hidden":false,"country":"Belgium","fullurl":"/company_page/eu-horizon-2020","logokey":"$Y11JsXnB1FT2S0h1lyXUQMAhH6bM0g2tSIdWQAjTFxivAoweBwRj4g","tagline":"","urlname":"/company_page/eu-horizon-2020","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE7vSzCgw","fundingtype":"Other","leadpartner":null,"investmentid":"f798780e-8753-4cfc-9398-0156d8ed8e66","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y11JsXnB1FT2S0h1lyXUQMAhH6bM0g2tSIdWQAjTFxivAoweBwRj4g","leadcaption":"","followupcaption":""}],"eventvisibility":"Private","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='\n\n
\n \n \n Private\n
'","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2650000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}